Loss of Dnmt3a and endogenous KrasG12D/+ cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis

Leukemia

Volumn 29, Issue 9, 2015, Pages 1847-1856

  Chang, Y I ^a,b   You, X ^a   Kong, G ^a   Ranheim, E A ^c   Wang, J ^a   Du, J ^a   Liu, Y ^a   Zhou, Y ^a   Ryu, M J ^a,d   Zhang, J ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c UNIVERSITY OF WISCONSIN   (United States)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; DNA METHYLTRANSFERASE 3A; INTERFERON; K RAS PROTEIN; DNA (CYTOSINE 5) METHYLTRANSFERASE; PROTEIN P21;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CELL COMPARTMENTALIZATION; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CONTROLLED STUDY; DOWN REGULATION; ENZYME DEFICIENCY; EPIGENETICS; ERYTHROPOIESIS; EXTRAMEDULLARY HEMATOPOIESIS; FLOW CYTOMETRY; GENE INTERACTION; GENE MUTATION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC TISSUE; HUMAN; INTERFERON PRODUCTION; LEUKEMOGENESIS; MONOCYTE; MOUSE; MYELOID LEUKEMIA; MYELOID PROGENITOR CELL; NEUTROPHIL; NONHUMAN; ONCOGENE K RAS; ONCOGENE N RAS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; SPLEEN; T LYMPHOCYTE; ANIMAL; CELL TRANSFORMATION; DISEASE MODEL; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIESIS; KNOCKOUT MOUSE; LEUKEMIA; METABOLISM; PATHOLOGY; PENETRANCE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DOWN-REGULATION; GENE DELETION; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; LEUKEMIA; LEUKEMIA, MYELOID; MICE; MICE, KNOCKOUT; MYELOID PROGENITOR CELLS; PENETRANCE; PHENOTYPE; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84940795296     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.85     Document Type: Article

References (33)

1. Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood 2012; 120: 3397-3406.
2. Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA 2004; 101: 597-602.
3. Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 2004; 113: 528-538.
4. Zhang J, Wang J, Liu Y, Sidik H, Young KH, Lodish HF et al. Oncogenic Krasinduced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood 2009; 113: 1304-1314.
5. Du J, Liu Y, Meline B, Kong G, Tan LX, Lo JC et al. Loss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals. Leukemia 2013; 27: 754-757.
6. Wang JY, Liu YG, Li ZY, Du J, Ryu MJ, Taylor PR et al. Endogenous oncogenic Nras mutation leads to aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. Blood 2010; 116: 5991-6002.
7. Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K et al. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood 2011; 117: 2022-2032.
8. Wang JY, Liu YG, Li ZY, Wang ZD, Tan LX, Ryu MJ et al. Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose-and cell typedependent manner. Blood 2011; 118: 368-379.
9. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012; 12: 599-612.
10. Dunbar AJ, Gondek LP, O'Keefe CL, Makishima H, Rataul MS, Szpurka H et al. 250 K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 2008; 68: 10349-10357.
11. Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B et al. Nextgeneration sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010; 28: 3858-3865.
12. Kato M, Yasui N, Seki M, Kishimoto H, Sato-Otsubo A, Hasegawa D et al. Aggressive transformation of juvenile myelomonocytic leukemia associated with duplication of oncogenic KRAS due to acquired uniparental disomy. J Pediatr 2013; 162: 1285-1288.
13. Chang YI, Damnernsawad A, Allen LK, Yang D, Ranheim EA, Young KH et al. Evaluation of allelic strength of human TET2 mutations and cooperation between Tet2 knockdown and oncogenic Nras mutation. Br J Haematol 2014; 166: 461-465.
14. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-2433.
15. Li KK, Luo LF, Shen Y, Xu J, Chen Z, Chen SJ. DNA methyltransferases in hematologic malignancies. Semin Hematol 2013; 50: 48-60.
16. Russler-Germain DA, Spencer DH, Young MA, Lamprecht TL, Miller CA, Fulton R et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 2014; 25: 442-454.
17. Kim SJ, Zhao H, Hardikar S, Singh AK, Goodell MA, Chen T. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood 2013; 122: 4086-4089.
18. Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2012; 44: 23-31.
19. Mayle A, Yang L, Rodriguez B, Zhou T, Chang E, Curry CV et al. Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood 2014; 125: 629-638.
20. Gao Q, Steine EJ, Barrasa MI, Hockemeyer D, Pawlak M, Fu D et al. Deletion of the de novo DNA methyltransferase Dnmt3a promotes lung tumor progression. Proc Natl Acad Sci USA 2011; 108: 18061-18066.
21. Network TCGAR. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074.
22. Nguyen S, Meletis K, Fu D, Jhaveri S, Jaenisch R. Ablation of de novo DNA methyltransferase Dnmt3a in the nervous system leads to neuromuscular defects and shortened lifespan. Dev Dyn 2007; 236: 1663-1676.
23. Kong G, Wunderlich M, Yang D, Ranheim EA, Young KH, Wang J et al. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. J Clin Invest 2014; 124: 2762-2773.
24. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science 1995; 269: 1427-1429.
25. Peters SL, Hlady RA, Opavsky J, Klinkebiel D, Pirruccello SJ, Talmon GA et al. Tumor suppressor functions of Dnmt3a and Dnmt3b in the prevention of malignant mouse lymphopoiesis. Leukemia 2014; 28: 1138-1142.
26. Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML et al. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol 2009; 7: e59.
27. Celik H, Mallaney C, Kothari A, Ostrander EL, Eultgen E, Martens A et al. Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation. Blood 2014; 125: 619-628.
28. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328-333.
29. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014; 20: 1472-1478.
30. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG et al. Agerelated clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371: 2488-2498.
31. Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371: 2477-2487.
32. Wang J, Kong G, Liu Y, Du J, Chang Y-I, Zhang X et al. Nras G12D/+ promotes leukemogenesis by aberrantly regulating haematopoietic stem cell functions. Blood 2013; 121: 5203-5207.
33. Parikh C, Subrahmanyam R, Ren R. Oncogenic NRAS rapidly and efficiently induces CMML-and AML-like diseases in mice. Blood 2006; 108: 2349-2357.